FCGR3A Recombinant Monoclonal Antibody

1. Conditioned media or microparticles released from obese omental adipose tissue were observed to increase CD16 and CCR5 expression on CD14(+)CD16(-) monocytes. This led to augmented migratory capacity of these monocytes towards the conditioned media from obese omental adipose tissue. PMID: 27677832
2. Research findings indicated no association between FCGR3A 158V/F alleles and susceptibility to systemic lupus erythematosus. PMID: 27914599
3. Elevated levels of CD16(+) Monocytes have been linked to Acute Rejection after Liver Transplantation. PMID: 29970436
4. Analysis of the Fc gamma receptor FCgammaRIIIA 158 V/f gene polymorphism revealed that all 100 immune thrombocytopenic purpura (ITP) patients carry the wild FcgammaRIIIa (FF) genotype. PMID: 28856973
5. CD16- monocyte subsets are upregulated in systemic lupus erythematous patients and may play a role in the pathogenesis and development of this disease. PMID: 28821990
6. CD16 expression and morphological maturity of neutrophils are associated with higher iron ferritin levels in major beta-thalassemia. PMID: 29729700
7. A proposed regulatory system for FCGR3A in human NK cells involves CpG dinucleotide sequences and concurrent DNA methylation, which confer developmental and cell type-specific transcriptional regulation. miR-218 provides an additional layer of posttranscriptional regulation during the maturation process. PMID: 29229679
8. Studies suggest that CD16-CD68-expressing macrophages might participate in ureteral neoplastic transformation. PMID: 29243545
9. FCGR3A V158F polymorphism appears to be associated with anti-drug antibodies production against monoclonal antibodies targeting tumor necrosis factor (TNF). This finding should be considered when determining the dosage and type of anti-TNF therapy in inflammatory bowel diseases patients. PMID: 29333082
10. Research has identified that CNVs (copy number variants) in the FCGR3A gene are associated with the risk of gout. The CNV in this locus exhibits different frequency distributions between gout patients and healthy subjects, particularly a higher frequency of the high FCGR3A copy number variant in gout patients. PMID: 28405828
11. Affimer proteins effectively inhibit immune complex binding to FcgammaRIIIa through competitive and allosteric mechanisms. PMID: 29247053
12. Analysis of the assembly and surface expression of FcepsilonR1alpha in cells demonstrates that CD16A associates equally well with human CD247 and FcepsilonR1gamma homodimers. PMID: 28652325
13. Lower copy numbers (PMID: 28355982
14. Memory-like differentiation in NK cells leads to enhanced IFN-gamma production triggered by leukemia targets or FcgammaRIIIa ligation. These licensed NK cells exhibit the highest functionality among the NK cell subsets studied. PMID: 27894857
15. A semi-mechanistic model incorporating target-mediated elimination accurately described rituximab pharmacokinetics in patients with CLL. This model revealed, for the first time, an influence of baseline target antigen count and the FCGR3A-158V/F polymorphism on rituximab target-mediated elimination. PMID: 27783363
16. The FCGR3A-V158F polymorphism could serve as a specific marker for predicting response to anti-TNFalpha therapy in psoriasis patients. PMID: 27044681
17. The FCGR3A V allele was correlated with the occurrence of late-onset neutropenia following rituximab treatment in patients with rheumatic diseases. PMID: 28270182
18. An association was observed between the antibody-dependent cellular cytotoxicity activity of adalimumab, an IgG reagent, and the FcgammaRIIIa -158V/F polymorphism (rs396991). PMID: 28913867
19. CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood-brain barrier, suggesting its potential as a therapeutic target for neuro-AIDS. PMID: 28754798
20. Analysis of the KIR/HLA-C complex and CD16A (48H/R/L,158V/F) gene polymorphisms in 52 colorectal cancer patients and 61 local healthy controls was conducted. PMID: 27519478
21. FcgammaRIIIa-pSyk cosignaling plays a role in modulating NA-TLR responses in human CD4(+) T cells by influencing the amounts and cellular distribution. These events are essential for understanding autoimmune pathology. PMID: 28500073
22. Research findings indicated no association between FCGR3A polymorphisms and Guillain-Barre Syndrome in a Brazilian population. PMID: 27609290
23. Intermediate CD14++CD16+monocytes might be closely related to the pathogenesis of atrial fibrillation and reflect functional remodeling of the left atrium. PMID: 26826137
24. An association exists between FcgammaRIIIa genetic polymorphisms and susceptibility to severe malaria anemia in children in western Kenya. PMID: 28427365
25. The FcgammaRIII3a-131H allele appears to have a protective role in autoantibody production in Chinese rheumatoid arthritis patients. PMID: 28112584
26. A combination of NMR and 1 microsecond all-atom computational simulations was used to identify unexpected contacts between the N45 N-glycan and CD16A polypeptide residues. PMID: 28613884
27. Research findings indicate that FCGR3A CNVs are a major risk factor for female sarcoidosis, and FCGR3B CNVs may also influence the development of sarcoidosis. PMID: 27059607
28. The FcgammaRIIIa V allele is associated with a pathological complete response benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ breast cancer. PMID: 27378608
29. CD16+ cells were significantly more frequent among Natural Killer (NK) cells lacking the inhibitory KIR (iKIR) KIR2DL1, KIR2DL3, and KIR3DL1 compared to those positive for any of these iKIR. This suggests that iKIR+ NK cells are less effective antibody-dependent cellular cytotoxicity effectors than iKIR- NK cells. PMID: 27732638
30. The association of CD16a-inducible NK cell-selective transcripts CD160 and XCL1 with kidney biopsies exhibiting antibody-mediated rejection provides evidence for NK cell CD16a activation in AMR. PMID: 27906829
31. While FcgammaR expression did not differ between immune thrombocytopenia (ITP) patients and controls, the FCGR3A (158V/F) polymorphism, known to enhance FcgammaRIII affinity to IgG, was overrepresented in ITP patients. PMID: 28142207
32. An increased fraction of CD16(high) CD62L(dim) neutrophils was shown to correlate with an improved survival rate. PMID: 28247912
33. Trastuzumab acidic variants exhibited reduced binding to the oncogene protein HER-2 (HER2) compared to basic variants. Both acidic and basic variants showed no significant changes in their binding to soluble CD16a receptors. PMID: 28087106
34. Research suggests that genetic polymorphisms within the FCGR3A gene are predisposing factors for urinary tract infections after kidney transplantation. PMID: 28315348
35. FCGR3A expression is significantly upregulated in human masticatory mucosa during wound healing. PMID: 28005267
36. Research indicates that genetic polymorphisms located within an enhancer of FCGR3A influence NK cell-mediated antibody-dependent cellular cytotoxicity. PMID: 27338556
37. CD16a was found to reside in Kupffer cells, contributing to the inhibition of liver tumor cell growth. PMID: 27082928
38. FcgammaRIIIA allelic distribution was comparable between pediatric Guillain-Barre syndrome patients and controls. PMID: 27064330
39. Anti-platelet drugs exhibit an immunomodulatory action by counteracting CD14(high)CD16(+) monocyte increases under pro-inflammatory conditions. This effect is dependent on the extent of P-selectin reduction. PMID: 27118470
40. Analysis of natural killer cell markers in renal transplantation, which play roles in acute rejection, revealed that CD56 and CD57 are elevated in the interstitial compartment of donor-specific antibody (DSA)-negative biopsies from patients with acute antibody-mediated rejection without C4d. CD16 is elevated in the glomerular compartment of DSA-positive biopsies. PMID: 26615051
41. Studies suggest that the Fc gamma receptor IIIA (FCGR3A) 158 V/F polymorphism can predict the treatment response to rituximab-based chemotherapy in non-Hodgkin lymphoma (NHL) patients. PMID: 27431582
42. Among nine patients with relapse, the incidences of the FCGR3A-158 variants VV, VF, and FF were 0 (0%), 8 (89%), and 1 (11%), respectively. These figures contrast with 13 (11%), 61 (52%), and 44 (37%) in the 118 patients without relapse. PMID: 27376362
43. Out of 36 DLBCL patients, the distributions of F/F, V/F, and V/V types of alleles of FcgammaRIIIA were 25%, 50%, and 25%, respectively. Overall survival in the F/F allele group was found to be lower than in the other two groups. However, overall response rates were similar across all groups. PMID: 26316483
44. Lower copy numbers (PMID: 26494566
45. This meta-analysis indicates that polymorphisms in the pathways of immune complex clearance, such as the FcgammaRIIIa, FcgammaRIIIb, and ITGAM genotypes, are potential susceptibility genes for neuropsychiatric systemic lupus erythematosus. PMID: 26773105
46. Data suggests a mechanism for the increased affinity of GASDALIE Fc for Fc receptor FcgammaRIIIa. PMID: 26850169
47. Single-nucleotide polymorphisms of the FCGR3A gene are associated with bloodstream infections after liver transplantation. PMID: 26517570
48. These results suggest that the structure and expression of the CD16 molecule differ among FcgammaRIIIa-V158F genotypes. The FcgammaRIIIa-V158F polymorphism might represent a haplotype with other SNPs in regulatory regions in Japanese subjects. PMID: 26582002
49. A method for determining the CNV status of the FCGR locus was developed. This method identified an association of CNV in FCGR3B with rheumatoid arthritis and established a functional relationship between CNV in the FCGR3A gene and CD16A expression. PMID: 25966632
50. KRAS wild-type chemorefractory metastatic colorectal cancer patients carrying the genotype FF of V158F may benefit from cetuximab-based therapy. PMID: 26363448

Show More

Hide All

HGNC: 3619

OMIM: 146740

KEGG: hsa:2214

STRING: 9606.ENSP00000356946

UniGene: Hs.372679